GlassScriptPhysician profile
Jonathan Ralph Edgette
NPI 1306562764
$1,495.30
in general payments reported to CMS, 2019-2025
30 companies · $161 in 2025
The $161 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $31.10 · 2023: $1,074 · 2024: $230 · 2025: $161.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,464.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,464.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $188.38 | 2023-2024 | |
| Novo Nordisk INC | $166.10 | 2023-2024 | Wegovy, Ozempic, Rybelsus |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $153.28 | 2023-2024 | Caplyta |
| Novartis Pharmaceuticals Corporation | $105.91 | 2023-2025 | |
| Lilly USA, LLC | $93.86 | 2023 | Mounjaro, Emgality, Reyvow |
| Bayer Healthcare Pharmaceuticals INC. | $78.87 | 2023 | |
| Neurocrine Biosciences, INC. | $78.48 | 2023 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $68.36 | 2022-2024 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $60.90 | 2023-2024 | Austedo Xr |
| Amgen INC. | $58.27 | 2023-2024 | Repatha, Otezla |
| Axsome Therapeutics, INC. | $37.57 | 2023 | Auvelity |
| Azurity Pharmaceuticals, INC. | $35.95 | 2024-2025 | Danziten, Horizant |
| Agios Pharmaceuticals, INC. | $33.69 | 2025 | Pyrukynd |
| Exact Sciences Corporation | $31.77 | 2023 | Cologuard Collection Kit |
| Geron Corporation | $31.60 | 2025 | Rytelo |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $30.00 | 2023 | Yupelri |
| Takeda Pharmaceuticals U.S.A., INC. | $28.11 | 2023 | Trintellix |
| Legend Biotech USA INC. | $25.73 | 2025 | Carvykti |
| Janssen Pharmaceuticals, INC | $18.10 | 2023 | Spravato |
| Jazz Pharmaceuticals INC. | $17.90 | 2025 | |
| Lundbeck LLC | $17.57 | 2023 | Rexulti |
| Paratek Pharmaceuticals, INC. | $16.19 | 2023 | Nuzyra |
| Glaxosmithkline, LLC. | $16.14 | 2023 | Trelegy Ellipta |
| Incyte Corporation | $16.10 | 2025 | Jakafi |
| Pfizer INC. | $15.12 | 2024 | |
| Dexcom, INC. | $14.83 | 2023 | Dexcom G6 Transmitter |
| Alkermes, INC. | $14.78 | 2024 | Vivitrol |
| Gilead Sciences, INC. | $14.70 | 2024 | |
| Seqirus USA INC | $14.06 | 2022 | |
| Idorsia Pharmaceuticals US INC | $12.98 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Edgette listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.